The Growth of Integrated Care Models in Urology.
Bladder cancer
Genitourinary cancers
Integrated health care systems
Integrative oncology
Multidisciplinary communication
Prostate cancer
Telehealth
Value-based purchasing
Journal
The Urologic clinics of North America
ISSN: 1558-318X
Titre abrégé: Urol Clin North Am
Pays: United States
ID NLM: 0423221
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
2
4
2021
pubmed:
3
4
2021
medline:
10
4
2021
Statut:
ppublish
Résumé
With heightened awareness of health care outcomes and efficiencies and reimbursement-based metrics, it is ever more important that urologists consider the effects of integrated care models on physicians/staff/clinics fulfillment and patient outcomes, and whether and how to optimally implement these models within their unique practice settings. Despite growing evidence that integrating care improves outcomes, uncertainty persists regarding which approach is most efficient and achievable in terms of specialty considerations and financial resources. In this article, we discuss strategies for integrating urologic care and its impact on current and future health care delivery.
Identifiants
pubmed: 33795056
pii: S0094-0143(20)30105-1
doi: 10.1016/j.ucl.2020.12.002
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
223-232Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure Dr M. Cookson has advisory roles with Astellas, Bayer, Janssen, and Merck. Dr N. Shore has research/consulting roles with AbbVie, Amgen, AstraZeneca, Astellas, Bayer, BMS, Clovis Oncology, Dendreon, Exact Imaging, Exact Sciences, Fergene, Ferring, Janssen, MDxHealth, Merck, Myovant, Novartis, Nymox, Pantarhei, Pfizer, Sanofi-Genzyme, and Tolmar.